Week 1 HW: Principles and Practices

Question 1:

Biological Engineering Application / Tool A Multiscale Computational Platform for Predictive Tissue Morphogenesis. I want to develop a computational–experimental platform that predicts tissue-level morphogenesis from gene regulatory, cellular, and mechanical inputs, with a particular focus on developmental defects and regenerative biology.

The core of the tool would integrate:

1. Single-cell transcriptomics and spatial transcriptomics (to capture gene expression states).
2. Agent-based models (e.g cellular Potts or vertex models) to represent cell–cell interactions, division, and differentiation.
3. Continuum mechanics (ECM stiffness gradients, stress fields) to model tissue-scale forces.

The platform would allow researchers to simulate counterfactual interventions—for example:

1. How altering ECM stiffness gradients changes tissue folding.
2. How perturbing signaling pathways affects cell fate distributions.
3. How genetic or mechanical defects propagate across scales during development.

Question 2:

Governance or Policy Goals for an Ethical Future Goal 1: Ensure Non-Malfeasance and Biological Safety Prevent misuse or harmful over-application of predictive morphogenesis tools.

    Sub-goal 1.1: Prohibit unvalidated clinical, reproductive, or enhancement uses of the tool.
    Sub-goal 1.2: Reduce dual-use risks by limiting applications that could optimise harmful biological interventions.

Goal 2: Maintain Epistemic Integrity and Responsible Use Ensure that model predictions are not treated as biological ground truth.

    Sub-goal 2.1: Require transparent reporting of model assumptions, uncertainty, and limits of validity.
    Sub-goal 2.2: Prevent “automation bias” by framing the tool as decision-support, not decision-making.

Question 3:

Purpose

What exists now:
    Oversight is fragmented—IRBs focus on experiments, not computational prediction tools.

Proposed change:
    Create a standing, interdisciplinary oversight consortium that evaluates high-impact biological simulation platforms.

Design

 Actors involved: Academic researchers, ethicists, developmental biologists, regulators.

 Functions:

    Risk classification of modeling tools,
    Issuing best-practice guidelines,
    Advising funders and journals.
    Modeled after aviation safety boards or financial stress-test bodies.

Assumptions

 Assumes cross-disciplinary consensus is achievable.
 Assumes advisory (not punitive) governance will be respected.

Risks of Failure & “Success”

 Failure risk: Bureaucratization and slow decision-making.
 Success risk: Centralized authority may become overly conservative.
 Mitigation: Keep the body advisory, adaptive, and periodically reviewed.

Question 5:

Priority: I would prioritize Option 1 (model transparency and uncertainty disclosure), with limited use of Option 2 (restricted licensing) for clearly high-risk applications.

Why: Option 1 scores best on feasibility, low burden, and not impeding research, while still reducing harm by preventing overconfidence and misuse. Option 2 is valuable for biosecurity, but only when narrowly applied; broad restrictions risk slowing legitimate science. Option 3 is useful for coordination but is slower and harder to implement.

Trade-offs: This approach favors prevention through norms and clarity over heavy enforcement, accepting some residual misuse risk to preserve open research.

Assumptions & uncertainties: It assumes researchers will take uncertainty disclosures seriously and that most harms arise from misinterpretation rather than malicious intent—both of which remain uncertain.